Data / Crowdfunding / Connecticut / Diant Pharma Inc.
Diant Pharma Inc.: crowdfunding raise on StartEngine Primary, LLC, $19,999 to $1,234,998 (2025)
Diant Pharma Inc., a corporation in Manchester, CT, filed a Form C with the SEC on March 12, 2025 to raise $19,999 to $1,234,998 in Series Seed-2 Preferred Stock through StartEngine Primary, LLC. The offering closed on April 30, 2025. In its most recent fiscal year it reported $1,530,991 in revenue and a net loss of $538,167, with 9 employees.
SpecStream is the live web data engine for teams and agents. It reads every Form C on SEC EDGAR each morning, and this page is that reading. Ask for your own cut (a portal, a state, a size, a revenue range) and new raises arrive in your sheet, CRM, Slack or agent as they land.
- Website
- www.diantpharma.com
- Funding portal
- StartEngine Primary, LLC
- Address
- 130 Utopia Road, Unit 12, Manchester, CT 06042
- Legal form
- Corporation
- Jurisdiction
- DE
- Incorporated
- July 2, 2019
- SEC CIK
- 0001949139
Offering terms
From the amendment filed March 12, 2025.
- Security
- Series Seed-2 Preferred Stock
- Price
- $1.88
- Target
- $19,999
- Maximum
- $1,234,998
- Deadline
- April 30, 2025
- Portal compensation
- 7 - 13 percent
Financials
From the Form C-AR filed May 8, 2026.
| Most recent fiscal year | Prior fiscal year | Source | |
|---|---|---|---|
| Revenue | $1,530,991 | $849,070 | sec.gov |
| Cost of goods sold | $881,307 | $279,180 | sec.gov |
| Net income | $-538,167 | $-414,051 | sec.gov |
| Taxes paid | $15,292 | $12,727 | sec.gov |
| Total assets | $1,690,032 | $1,766,948 | sec.gov |
| Cash | $29,330 | $55,455 | sec.gov |
| Accounts receivable | $103,276 | $0 | sec.gov |
| Short-term debt | $265,049 | $104,358 | sec.gov |
| Long-term debt | $190,406 | $0 | sec.gov |
Filings
| Filed | Filing | Target | Maximum | Deadline | Note | Source |
|---|---|---|---|---|---|---|
| May 8, 2026 | Annual report | Not listed | Not listed | sec.gov | ||
| May 8, 2025 | Progress update | $19,999 | $1,234,998 | April 30, 2025 | At the close of the offering, the issuer closed on $0.00 and 0 number of securities. | sec.gov |
| March 12, 2025 | Amendment | $19,999 | $1,234,998 | April 30, 2025 | Updated capital resources, and D&O to add COO, removed CTO. Revised FDA product use on campaign page. Increased authorized shares. Lowered minimum to $20K and updated use of proceeds. | sec.gov |
| December 26, 2024 | Progress update | $123,999 | $1,234,998 | March 12, 2025 | The issuer has raised over 100% ($140,643.38) of the offering target amount ($123,999.16). | sec.gov |
| December 11, 2024 | Offering | $123,999 | $1,234,998 | March 12, 2025 | sec.gov |
Updated May 8, 2026. Read from SEC EDGAR. Public domain (U.S. government work). Financials are as each company reported them in its Form C, unaudited unless the filing says otherwise. Websites are the ones the companies declared to the SEC. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.